Glucocorticosteroids increase cell entry by hepatitis C virus.
OBJECTIVE
Corticosteroids are used as immunosuppressants in patients with autoimmune disorders and transplant recipients. However, these drugs worsen hepatitis C virus (HCV) recurrence after liver transplantation, suggesting that they may directly exacerbate HCV infection.


METHODS
The influence of immunosuppressive drugs on HCV replication, assembly, and entry was assessed in Huh-7.5 cells and primary human hepatocytes using cell culture- and patient-derived HCV. Replication was quantified by immunofluorescence, luciferase assays, quantitative reverse-transcriptase polymerase chain reaction, or core enzyme-linked immunosorbent assays. Expression of HCV entry factors was evaluated by cell sorting and immunoblot analyses.


RESULTS
Glucocorticosteroids slightly reduced HCV RNA replication but increased efficiency of HCV entry by up to 10-fold. This was independent of HCV genotype but specific to HCV because vesicular stomatitis virus glycoprotein-dependent infection was not affected by these drugs. The increase in HCV entry was accompanied by up-regulation of messenger RNA and protein levels of occludin and the scavenger receptor class B type I-2 host cell proteins required for HCV infection; increase of entry by glucocorticosteroids was ablated by RU-486, an inhibitor of glucocorticosteroid signaling. Glucocorticosteroids increased propagation of cell culture-derived HCV approximately 5- to 10-fold in partially differentiated human hepatoma cells and increased infection of primary human hepatocytes by cell culture- and patient-derived HCV.


CONCLUSIONS
Glucocorticosteroides specifically increase HCV entry by up-regulating the cell entry factors occludin and scavenger receptor class B type I. Our data suggest that the potential effects of high-dose glucocorticosteroids on HCV infection in vivo may be due to increased HCV dissemination.
Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany.
Sandra
S
Ciesek
Eike
E
Steinmann
Markus
M
Iken
Michael
M
Ott
Fabian A
FA
Helfritz
Ilka
I
Wappler
Michael P
MP
Manns
Heiner
H
Wedemeyer
Thomas
T
Pietschmann
D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D005938:Glucocorticoids / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism / Q000821:virology; D006727:Hormone Antagonists / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008565:Membrane Proteins / Q000235:genetics; D015735:Mifepristone / Q000494:pharmacology; D062793:Occludin; D011239:Prednisolone / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D012367:RNA, Viral / Q000096:biosynthesis; D051122:Scavenger Receptors, Class B / Q000235:genetics; D013997:Time Factors; D053586:Virus Internalization / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects
D005938:Glucocorticoids; D006727:Hormone Antagonists; D007166:Immunosuppressive Agents; D008565:Membrane Proteins; C568985:OCLN protein, human; D062793:Occludin; D012333:RNA, Messenger; D012367:RNA, Viral; C495124:SCARB1 protein, human; D051122:Scavenger Receptors, Class B; D015735:Mifepristone; D011239:Prednisolone